BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

587 related articles for article (PubMed ID: 26038096)

  • 21. Pharmacokinetics in stable kidney transplant recipients after conversion from twice-daily to once-daily tacrolimus formulations.
    van Hooff J; Van der Walt I; Kallmeyer J; Miller D; Dawood S; Moosa MR; Christiaans M; Karpf C; Undre N
    Ther Drug Monit; 2012 Feb; 34(1):46-52. PubMed ID: 22249344
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Conversion from Prograf to Advagraf in adolescents with stable liver transplants: comparative pharmacokinetics and 1-year follow-up.
    Carcas-Sansuán AJ; Hierro L; Almeida-Paulo GN; Frauca E; Tong HY; Díaz C; Piñana E; Frías-Iniesta J; Jara P
    Liver Transpl; 2013 Oct; 19(10):1151-8. PubMed ID: 23894093
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetic modeling and development of Bayesian estimators in kidney transplant patients receiving the tacrolimus once-daily formulation.
    Saint-Marcoux F; Debord J; Undre N; Rousseau A; Marquet P
    Ther Drug Monit; 2010 Apr; 32(2):129-35. PubMed ID: 20110850
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of pharmacokinetics and pharmacogenetics of once- and twice-daily tacrolimus in the early stage after renal transplantation.
    Niioka T; Satoh S; Kagaya H; Numakura K; Inoue T; Saito M; Narita S; Tsuchiya N; Habuchi T; Miura M
    Transplantation; 2012 Nov; 94(10):1013-9. PubMed ID: 23073468
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Two years postconversion from a prograf-based regimen to a once-daily tacrolimus extended-release formulation in stable kidney transplant recipients.
    Alloway R; Steinberg S; Khalil K; Gourishankar S; Miller J; Norman D; Hariharan S; Pirsch J; Matas A; Zaltzman J; Wisemandle K; Fitzsimmons W; First MR
    Transplantation; 2007 Jun; 83(12):1648-51. PubMed ID: 17589351
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics of once- versus twice-daily tacrolimus formulations in kidney transplant patients receiving expanded criteria deceased donor organs: a single-center, randomized study.
    Cabello M; García P; González-Molina M; Díez de los Rios MJ; García-Sáiz M; Gutiérrez C; López V; Sola E; Burgos D; Hernández D
    Transplant Proc; 2010 Oct; 42(8):3038-40. PubMed ID: 20970603
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Improved adherence to tacrolimus once-daily formulation in renal recipients: a randomized controlled trial using electronic monitoring.
    Kuypers DR; Peeters PC; Sennesael JJ; Kianda MN; Vrijens B; Kristanto P; Dobbels F; Vanrenterghem Y; Kanaan N;
    Transplantation; 2013 Jan; 95(2):333-40. PubMed ID: 23263559
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lower variability in 24-hour exposure during once-daily compared to twice-daily tacrolimus formulation in kidney transplantation.
    Stifft F; Stolk LM; Undre N; van Hooff JP; Christiaans MH
    Transplantation; 2014 Apr; 97(7):775-80. PubMed ID: 24686426
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Population pharmacokinetics and Bayesian estimation of tacrolimus exposure in renal transplant recipients on a new once-daily formulation.
    Benkali K; Rostaing L; Premaud A; Woillard JB; Saint-Marcoux F; Urien S; Kamar N; Marquet P; Rousseau A
    Clin Pharmacokinet; 2010 Oct; 49(10):683-92. PubMed ID: 20818834
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A UK analysis of the cost of switching renal transplant patients from an immediate-release to a prolonged-release formulation of tacrolimus based on differences in trough concentration variability.
    Muduma G; Odeyemi I; Pollock RF
    J Med Econ; 2014 Jul; 17(7):520-6. PubMed ID: 24754700
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The once-daily formulation of tacrolimus: a step forward in kidney transplantation?
    Hougardy JM; de Jonge H; Kuypers D; Abramowicz D
    Transplantation; 2012 Feb; 93(3):241-3. PubMed ID: 22234346
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Conversion from twice- to once-daily tacrolimus in pediatric kidney recipients: a pharmacokinetic and bioequivalence study.
    Lapeyraque AL; Kassir N; Théorêt Y; Krajinovic M; Clermont MJ; Litalien C; Phan V
    Pediatr Nephrol; 2014 Jun; 29(6):1081-8. PubMed ID: 24435759
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lower variability of tacrolimus trough concentration after conversion from prograf to advagraf in stable kidney transplant recipients.
    Wu MJ; Cheng CY; Chen CH; Wu WP; Cheng CH; Yu DM; Chuang YW; Shu KH
    Transplantation; 2011 Sep; 92(6):648-52. PubMed ID: 21912349
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Once-daily tacrolimus extended release formulation: experience at 2 years postconversion from a Prograf-based regimen in stable liver transplant recipients.
    Florman S; Alloway R; Kalayoglu M; Punch J; Bak T; Melancon J; Klintmalm G; Busque S; Charlton M; Lake J; Dhadda S; Wisemandle K; Wirth M; Fitzsimmons W; Holman J; First MR
    Transplantation; 2007 Jun; 83(12):1639-42. PubMed ID: 17589349
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Budget impact of switching from an immediate-release to a prolonged-release formulation of tacrolimus in renal transplant recipients in the UK based on differences in adherence.
    Muduma G; Odeyemi I; Smith-Palmer J; Pollock RF
    Patient Prefer Adherence; 2014; 8():391-9. PubMed ID: 24729687
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics for once-daily versus twice-daily tacrolimus formulations in de novo liver transplantation: a randomized, open-label trial.
    Fischer L; Trunečka P; Gridelli B; Roy A; Vitale A; Valdivieso A; Varo E; Seehofer D; Lynch S; Samuel D; Ericzon BG; Boudjema K; Karpf C; Undre N
    Liver Transpl; 2011 Feb; 17(2):167-77. PubMed ID: 21280190
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of pharmacokinetics and pathology for low-dose tacrolimus once-daily and twice-daily in living kidney transplantation: prospective trial in once-daily versus twice-daily tacrolimus.
    Tsuchiya T; Ishida H; Tanabe T; Shimizu T; Honda K; Omoto K; Tanabe K
    Transplantation; 2013 Jul; 96(2):198-204. PubMed ID: 23792649
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Conversion from Prograf to Advagraf among kidney transplant recipients results in sustained decrease in tacrolimus exposure.
    Hougardy JM; Broeders N; Kianda M; Massart A; Madhoun P; Le Moine A; Hoang AD; Mikhalski D; Wissing KM; Abramowicz D
    Transplantation; 2011 Mar; 91(5):566-9. PubMed ID: 21192316
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Conversion of stable kidney transplant recipients from a twice-daily prograf to a once-daily tacrolimus formulation: a short-term study on its effects on glucose metabolism.
    Uchida J; Kuwabara N; Machida Y; Iwai T; Naganuma T; Kumada N; Nakatani T
    Transplant Proc; 2012 Jan; 44(1):128-33. PubMed ID: 22310596
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics of tacrolimus in adult renal transplant recipients.
    Naik P; Madhavarapu M; Mayur P; Nayak KS; Sritharan V
    Drug Metabol Drug Interact; 2012; 27(3):151-5. PubMed ID: 23089531
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.